Increasing Number of Surgeries Due To High Burden of Chronic Disease Is Fostering the Growth of the Surgical Blades Market

 

Surgical Blades Market

Surgical blades are essential and have to be held up to the highest professional standards of quality. These very sharp medical tools and are a vital part of ensuring that every operation perform is conducted safely and to the very highest standards. There are a number of different kinds of surgical blades available in the market. Straightness in these blades is typically used in invasive surgery involving the inner abdominal cavity, as they are able to cut downwards through the tissue without the knife accidentally ripping through the lining of the stomach.

 A growing number of surgeries around the globe is propelling the growth of the surgical blade market. Increasing cases of road accidents is another key factor propelling the growth of the surgical blade market. According to the World Health Organization, every year the lives of approximately 1.35 million people are cut short as a result of a road traffic crash. Between 20 and 50 million more people suffer non-fatal injuries, with many incurring a disability as a result of their injury. Moreover, the increasing prevalence of chronic disease coupled with the growing geriatric population is again augmenting the growth of the market. Increasing global healthcare expenditure by the government for improving healthcare facilities is further projected to bolster the growth of the surgical blade market.

North America is projected to exhibit significant growth over the forecast period and this is attributed to the increasing number of minimally invasive surgeries in the region. According to the American Society of Plastic Surgeons, in 2019, minimally invasive cosmetic procedures grew at a slightly higher rate. Among the 16.3 million cosmetics minimally invasive procedure performed in 2019, up 2 percent compared to 2018 data, the top 5 were: Botulinum toxin type A (7.69 million procedures), Soft tissue fillers (2.72 million procedures), Chemical peel (1.38 million procedures), Laser hair removal (1.0 million procedures), and Intense Pulsed Light (IPL) treatment (685,755 procedures).

Key Developments:

1.     In October 2020, Entrepix Medical, LLC, medical technology has announced the launch of Planatome® Technology. This patented technology produces a radically unique, patient-focused surgical blade with an ultra-smooth, precise, and consistent cutting surface that dramatically minimizes surgically-induced tissue trauma.

2.     In May 2019, Surgical Specialties Corporation (SSC) announced the launch of Caliber Ophthalmics, a new business division.

3.     In May 2019, Obp, the global developer of single-use, self-contained, illuminating medical devices, announced the launch of ONETRAC LX, a new and improved line of single-use, cordless surgical retractors with an integrated multi-LED light source and dual smoke evacuation channels.

 

Comments

Post a Comment

Popular posts from this blog

The Emergence of COVID-19 to Augment Growth of the Outsourced Drug Discovery Market

Image
  With billions of dollars in research and development costs, pharmaceutical companies around the world are always looking for new ways to address their production processes in a cost-effective manner. One way to achieve this is through outsourcing drug discovery and development services. This type of service refers to the collaboration between small and large biotech and biotechnology companies to conduct research and development activities aimed at finding better solutions to the company's core chemical concerns. Outsourcing of these drug discovery services has enabled established pharmaceutical and biotechnology companies to focus on the development of new products that can bring about significant therapeutic change and provide tangible advantages to the company's shareholders. Contract research organizations manage almost all aspects of drug discovery. Market Dynamics I ncreasing demand for outsourcing analytical testing and clinical trial services, growing R&D ex...
Read more

Otoscope Market Is Gaining Major Traction with Industry Leader Otonexus Medical Technologies Introducing Ultrasound Sensor, Which Aids Middle-Ear Infection Diagnosis

Image
  An otoscope or auricular ear picker is a simple health care tool that is used to inspect the outer ear. Many health care professionals utilize otoscopes to examine ear infections during routine check-ups and to also screen for serious ear disorders. An otoscope possibly provides a more detailed view of the external ear canal and/or ear drum or eardrum. Otoscope or also referred to as auriscope is mainly used to look into eyes. The demand for these medical devices has been on a rise in the recent past. This is typically due to the fact that there is a high burden of ENT-related diseases across the globe. As per the World Health Organization (WHO), by 2050, around 2.5 billion people are estimated to have some degree of hearing loss worldwide. Similarly, there is a heavy burden of sinusitis cases. As per the Sinusitis & Allergy Wellness Center, around 30 million adults in the U.S. are impacted with sinusitis annually. Such a high prevalence of ENT disorders has accelerated the d...
Read more

The Number of Cancer Survivors Is Projected To Increase to 22.2 Million By 2030 Fostering Oncology Drug Pipeline Analysis Market

Image
  North America is estimated to dominate the global oncology drug pipeline analysis market in the near future and this is attributed to the high prevalence of cancer and increasing launch of various novel drugs with improved efficacy. According to the National Cancer Institute, as of January 2019, there were an estimated 16.9 million cancer survivors in the United States. The number of cancer survivors is projected to increase to 22.2 million by 2030. The oncology field is experiencing significant growth and this is attributed to the increasing development of various novel therapies for the treatment of cancer. For instance, in February 2021, Rhizen Pharmaceuticals AG, a clinical-stage, oncology-focused biopharma company, with a 50% stake owned by Alembic Pharmaceuticals and the rest by its Indian CEO Swaroop Vakkalanka, has announced that its the novel, next-generation PI3K-delta inhibitor Umbralisib (Ukoniq) has secured U.S. FDA accelerated approval for the treatment of blood c...
Read more